FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023146192> ?p ?o ?g. }

• W2023146192 endingPage "6" @default.
• W2023146192 startingPage "1" @default.
• W2023146192 abstract "Millions of patients are treated with opioid analgesics (OpAs) to relieve pain. Unfortunately, these medications are subject to abuse and/or unintended misuse. Abuse deterrent formulations (ADFs) represent an intervention strategy to decrease abuse/misuse without affecting patient access. The Food and Drug Administration (FDA) has issued Draft Guidance “Abuse deterrent opioids, Evaluation and Labeling” and is currently actively pursuing scientific input on this issue. The development of ADF technologies was reviewed using peer reviewed journals describing OpA post marketing studies, web sites containing FDA announcements on product approvals and manufacturer product use profiles. Reviewed is the FDA recent approval of a product label describing the abuse deterrent characteristics of OxyContin® (physical barrier formulation), and the FDA determination that studies were insufficient for an Opana® (physical barrier) ADF label. Additional reviewed marketed OpAs with ADF technologies include: Suboxone® and Embeda® (opioid agonist/antagonist combinations), Oxecta® (aversion technology), and Nucynta® (physical barrier). Reviewed ADF technologies currently in development include: new physical barrier and aversion technologies, an innovative extended release formulation as well as novel polymer–opioid conjugates. As ADF technologies are part of a comprehensive intervention strategy to promote safe OpA use, additional components including governmental, community, and educational initiatives are reviewed. The outcomes of the recent ADF labeling applications for OxyContin® (Tier 3 approval) and Opana® (non-approval) suggest that the threshold for ADF labeling will be appropriately high. The presented findings indicate that ADF technologies can be a critical component of a comprehensive strategy to promote the safe and effective use of OpAs." @default.
• W2023146192 created "2016-06-24" @default.
• W2023146192 creator A5027219701 @default.
• W2023146192 creator A5038799059 @default.
• W2023146192 creator A5062547153 @default.
• W2023146192 creator A5065913211 @default.
• W2023146192 creator A5090963349 @default.
• W2023146192 date "2014-05-01" @default.
• W2023146192 modified "2023-10-14" @default.
• W2023146192 title "Development and impact of prescription opioid abuse deterrent formulation technologies" @default.
• W2023146192 cites W1503812641 @default.
• W2023146192 cites W1553227309 @default.
• W2023146192 cites W1719756019 @default.
• W2023146192 cites W1765108219 @default.
• W2023146192 cites W1923689435 @default.
• W2023146192 cites W1955439479 @default.
• W2023146192 cites W1967063767 @default.
• W2023146192 cites W1993178542 @default.
• W2023146192 cites W1998276346 @default.
• W2023146192 cites W2001029010 @default.
• W2023146192 cites W2007308041 @default.
• W2023146192 cites W2012127588 @default.
• W2023146192 cites W2024737247 @default.
• W2023146192 cites W2032474664 @default.
• W2023146192 cites W2038389290 @default.
• W2023146192 cites W2051105828 @default.
• W2023146192 cites W2066553562 @default.
• W2023146192 cites W2068871297 @default.
• W2023146192 cites W2071956502 @default.
• W2023146192 cites W2084790627 @default.
• W2023146192 cites W2089911395 @default.
• W2023146192 cites W2090195992 @default.
• W2023146192 cites W2128082475 @default.
• W2023146192 cites W2128133826 @default.
• W2023146192 cites W2132989145 @default.
• W2023146192 cites W2139852527 @default.
• W2023146192 cites W2139947332 @default.
• W2023146192 cites W2145549479 @default.
• W2023146192 cites W2157551435 @default.
• W2023146192 cites W2396045664 @default.
• W2023146192 cites W3138871262 @default.
• W2023146192 cites W3191694709 @default.
• W2023146192 doi "https://doi.org/10.1016/j.drugalcdep.2014.02.006" @default.
• W2023146192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24613631" @default.
• W2023146192 hasPublicationYear "2014" @default.
• W2023146192 type Work @default.
• W2023146192 sameAs 2023146192 @default.
• W2023146192 citedByCount "53" @default.
• W2023146192 countsByYear W20231461922014 @default.
• W2023146192 countsByYear W20231461922015 @default.
• W2023146192 countsByYear W20231461922016 @default.
• W2023146192 countsByYear W20231461922017 @default.
• W2023146192 countsByYear W20231461922018 @default.
• W2023146192 countsByYear W20231461922019 @default.
• W2023146192 countsByYear W20231461922020 @default.
• W2023146192 countsByYear W20231461922021 @default.
• W2023146192 countsByYear W20231461922022 @default.
• W2023146192 crossrefType "journal-article" @default.
• W2023146192 hasAuthorship W2023146192A5027219701 @default.
• W2023146192 hasAuthorship W2023146192A5038799059 @default.
• W2023146192 hasAuthorship W2023146192A5062547153 @default.
• W2023146192 hasAuthorship W2023146192A5065913211 @default.
• W2023146192 hasAuthorship W2023146192A5090963349 @default.
• W2023146192 hasConcept C118552586 @default.
• W2023146192 hasConcept C126322002 @default.
• W2023146192 hasConcept C144133560 @default.
• W2023146192 hasConcept C170493617 @default.
• W2023146192 hasConcept C2426938 @default.
• W2023146192 hasConcept C2524010 @default.
• W2023146192 hasConcept C2778858636 @default.
• W2023146192 hasConcept C2780665704 @default.
• W2023146192 hasConcept C2781063702 @default.
• W2023146192 hasConcept C2910999556 @default.
• W2023146192 hasConcept C33923547 @default.
• W2023146192 hasConcept C71924100 @default.
• W2023146192 hasConcept C90673727 @default.
• W2023146192 hasConcept C98274493 @default.
• W2023146192 hasConceptScore W2023146192C118552586 @default.
• W2023146192 hasConceptScore W2023146192C126322002 @default.
• W2023146192 hasConceptScore W2023146192C144133560 @default.
• W2023146192 hasConceptScore W2023146192C170493617 @default.
• W2023146192 hasConceptScore W2023146192C2426938 @default.
• W2023146192 hasConceptScore W2023146192C2524010 @default.
• W2023146192 hasConceptScore W2023146192C2778858636 @default.
• W2023146192 hasConceptScore W2023146192C2780665704 @default.
• W2023146192 hasConceptScore W2023146192C2781063702 @default.
• W2023146192 hasConceptScore W2023146192C2910999556 @default.
• W2023146192 hasConceptScore W2023146192C33923547 @default.
• W2023146192 hasConceptScore W2023146192C71924100 @default.
• W2023146192 hasConceptScore W2023146192C90673727 @default.
• W2023146192 hasConceptScore W2023146192C98274493 @default.
• W2023146192 hasLocation W20231461921 @default.
• W2023146192 hasLocation W20231461922 @default.
• W2023146192 hasOpenAccess W2023146192 @default.
• W2023146192 hasPrimaryLocation W20231461921 @default.
• W2023146192 hasRelatedWork W2293922742 @default.
• W2023146192 hasRelatedWork W2413810328 @default.
• W2023146192 hasRelatedWork W2786238877 @default.

• next